Reo Viruses

2/25/2019 https://emedicine.medscape.
com/article/227348-print
emedicine.medscape.com
Reoviruses
Updated: Mar 03, 2017
Author: Andrew Stevenson Joel Chandranesan, MBBS; Chief Editor: Mark R Wallace, MD, FACP, FIDSA
Overview
Background
The family Reoviridae is divided into 9 genera, 4 of which—Orthoreovirus, Coltivirus, Rotavirus, and Orbivirus —can infect
humans and animals. Four other genera infect only plants and insects, and one infects fish. Although almost 100 orbivirus
serotypes are known, only 3 serotypes of orthoreovirus and 2 of coltivirus have been identified. The genus Rotavirus contains 3
groups, A, B, and C, with group A causing most outbreaks of disease. Both orthoreoviruses and orbiviruses contain 10
segments of double-stranded RNA. Rotaviruses contain 11 genome segments, and coltiviruses have 12 segments.
Reovirus is now used as a therapeutic agent in the treatment of various types of malignancy. Reolysin, a strain of reovirus, has
been studied extensively as an anticancer agent in the treatment of head and neck cancers, metastatic melanoma, and other
solid-organ tumors.[1]
Structure and Composition

The virions of Reoviridae family viruses measure 60-80 nm in diameter and possess 2 concentric capsid shells, each of which is
icosahedral. No envelope is present. The inner capsids of all genera display sharply defined subunits; the outer capsids of
rotaviruses and orbiviruses lack well-defined subunit structures. The genome consists of double-stranded RNA in 10-12 discrete
segments, with a total genome size of 16-27 kilobase pair (kbp), depending on the genus. The double-shelled particle is the
complete infectious form of the virus. The individual RNA segments vary in size from 680 base pair (bp), ie, rotavirus, to 3900
bp, ie, orthoreovirus. The virion core contains several enzymes needed for transcription and capping of viral RNA.
Reoviruses are unusually stable to heat, to a pH range of 3.0-9.0, and to lipid solvents, but they are inactivated by 95% ethanol,
phenol, and chlorine.
The first human orthoreovirus was isolated in 1953 from a rectal swab collected from a healthy child and was originally the
prototype for echovirus type 10 of the Picornaviridae family. Subsequently, 3 serotypes were identified, and these agents,
designated as reovirus, were placed into the Reoviridae family. In 1959, Sabin proposed the name reovirus to reflect the fact
that viruses of this group had been isolated from the respiratory and enteric tracts and were orphan (reo) viruses without known
associated disease. From these early isolation studies, the respiratory and enteric tracts are assumed to represent the natural
portals of entry for reoviruses into the host.
The 3 serotypes share a common group antigen as detected with complement fixation.
Reoviruses are ubiquitous in nature, but their role in human disease is vague. Numerous early reports noted their association
with human disease; however, during the last 2 decades, few cases of human disease have been reported. These viruses also
have been evaluated extensively in studies involving laboratory animals.
Characteristics of the Pathogen

https://emedicine.medscape.com/article/227348-print 1/17
2/25/2019 https://emedicine.medscape.com/article/227348-print
Reoviruses (which also are called orthoreoviruses to avoid confusion with the family Reoviridae) are nonenveloped viruses.
Reovirus particles are composed of an inner protein shell (ie, core) of a diameter of 60 nm, which is surrounded by an outer
protein shell (ie, outer capsid) that measures 81 nm in diameter. The core is composed of 3 major (ie, lambda-1, lambda-2,
sigma-2) and several minor proteins that surround 10 segments of double-stranded RNA. The virions also contain 3
nonstructural proteins. Reoviruses are moderately heat-stable, stable through a wide pH range, and stable in aerosols,
particularly when the relative humidity is high.
Reoviruses replicate with a cytopathic effect in a large number of tissue culture systems of both primate and other animal origin.
For recovery from clinical material, monkey kidney tissue cultures are satisfactory. Because of their widespread prevalence in
nature and the ease of infection in laboratory animals, reoviruses have been used widely in pathogenicity studies.[2, 3, 4]
Orbivirus
Orbiviruses commonly infect insects, and many can be transmitted by insects to vertebrates. More than 100 serotypes have
been identified. Serious animal pathogens include bluetongue virus of sheep and African horse sickness virus. Antibodies are
found in many vertebrates, including humans. The genome consists of 10 segments of double-stranded RNA. The replicative
cycle is similar to that of reoviruses. In contrast with the general stability of other reoviruses, orbiviruses are inactivated by low
pH.
Orungo virus, isolated in Africa, has been implicated in an acute illness with myalgias and headache. Lebombo virus is another
orbivirus isolated from humans in Africa. Kemerovo virus has been implicated in neurologic infections in central Europe and
Russia. Serologic evidence of infection with Lipovnik or Tribec virus has been demonstrated in patients with polyradiculitis in the
former Czechoslovakia. Changuinola virus has been isolated from humans in Panama.
Coltivirus
Coltiviruses resemble the orbiviruses in size and in having 2 capsids. These viruses contain 12 RNA segments. Colorado tick
fever (CTF), Salmon River virus (in Idaho), Eyach virus (in Germany and France), isolate S6-14-03 (in California), Banna virus,
Beijing virus, and Gansu virus (in China) either are proved or suspected of causing human disease.
Coloradotick fever
During early investigations of Rocky Mountain spotted fever (RMSF), sporadic cases of an illness that followed a tick bite were
recognized. This illness differed from RMSF in that the characteristic skin rash was absent. Because this new illness was
thought to occur predominantly in Colorado, it was named CTF to distinguish it from the more severe RMSF. Mountain fever and
mountain tick fever are other names for this disease. The etiologic agent was recognized as a virus in 1946. CTF virus is the
prototype species for the genus Coltivirus of the family Reoviridae. CTF virus has a genome that consists of 12 segments of
double-stranded RNA. The virus is transmitted to mammals, including humans, principally by the adult Rocky Mountain wood
tick (ie, Dermacentor andersoni), and exposure to the virus is therefore restricted to the vector habitat. Clinical cases peak
between May and July.
Historically, CTF has been the most frequently reported arboviral disease in the United States. Nevertheless, it is considered an
underdiagnosed condition. Viral maintenance is achieved via larval and nymphal stages of D andersoni and various rodent
species.
In most cases, a history of tick bite can be obtained, but, occasionally, only body contact with a tick is remembered. In certain
instances, the bite has been unnoticed, and only a history of having been in a tick-infested area can be elicited. Occasionally,
the tick may be found imbedded in the skin only after very careful examination with particularly close observation of body folds,
skin creases, and areas with hair. The illness occurs primarily in spring and summer, with most cases occurring in April and May
at lower altitudes and in June and July at higher elevations. The disease may affect persons of any age.
Rotavirus
Infection with human rotavirus (HRV) appears to cause a substantial portion of cases of gastroenteritis in children aged 6
months to 2 years. The rotavirus particle consists of an 11 double-stranded RNA genome enclosed in a double-shelled capsid.
The outer shell is composed of a major glycoprotein with a molecular weight of 34,000 (ie, viral protein [VP]7) and a minor,
trypsin-sensitive protein with a molecular weight of 84,000 (ie, VP4, previously designated VP3). Four proteins (ie, VP1, VP2,
VP3, VP6) make up the virus core. Six nonstructural (NS) proteins (ie, NS53, NS34, NS35, NS28, NS26, NS12) are also
produced during rotavirus infection.
Trypsin cleavage of VP4, which yields 2 polypeptides, VP8 and VP5, with molecular weights of 27,000 and 58,000, respectively,
is required for the activation of infectivity. Originally, serotyping was based solely on differences in the VP7 protein because
animals hyperimmunized with rotaviruses develop most neutralizing antibody to this protein. Cross-neutralization studies
conducted with these hyperimmune sera readily separated the strains into VP7 serotypes. Later, a dual serotyping scheme was
developed when VP4 was discovered to be the dominant neutralization protein in some cases. Rotavirus serotypes include a
description of both the VP4 (protease-sensitive protein, P) and the VP7 (glycoprotein, G) types.
HRVs belonging to 11 G serotypes have been isolated, but the vast majority have been identified as G1, G2, G3, or G4, and
strains belonging to these G types have commonly been designated as serotype 1, 2, 3, or 4, respectively. The severity of
illness caused by viruses that belong to these 4 serotypes varies little, if at all. At least 6 different HRV P types have been
identified. P type 1a, the most common, is usually associated with G types 1, 3, or 4; whereas, P type 1b is usually associated
with G type 2.
Rotaviruses are closely related to reoviruses in terms of morphology and strategy of replication.
Epidemiology of Reoviruses
Reovirus
Reoviruses cause many inapparent infections because most people have serum antibodies by early adulthood. Antibodies are
also present in other species. All 3 types have been recovered from healthy children, from young children during outbreaks of
minor febrile illness, and from children with diarrhea or enteritis. Human volunteer studies have failed to demonstrate a clear
cause-and-effect relationship between reoviruses and human illness. The method of transmission of reoviruses is unknown.
However, because these viruses are recovered most frequently from the feces, primary spread seems most likely to be by the
fecal-oral route. Because the reoviruses are stable in aerosols and because respiratory illness has been associated with
reovirus infections, this route is an additional possibility.
Coloradotick fever
CTF is the most common arboviral disease among humans in the United States. It has been reported from at least 11 Western
states in the United States and from Alberta and British Columbia in Canada. In a 2015 study of 75 cases of CTF from 2002 to
2012, Wyoming had the highest annual incidence, followed by Montana and Utah.[5] CTF is transmitted to people by the adult
hard-shelled wood tick D andersoni. The virus has been found in as many as 14% of these ticks harvested in endemic areas
and is maintained in rather complex cycles between the tick vector and the host animals.
Both male and female adult ticks can transmit infection to humans, and the period of attachment required for transmission of the
virus may be very brief. In rare cases, CTF has developed in persons who did not travel to areas of known risk; for example, in
persons exposed to ticks brought home on clothing of family members and by transfusion. Most cases occur in May and June,
when adult ticks are most active, but infections occurring from March to November have been reported. CTF affects young and
old persons who, through occupational or recreational activities, come into contact with D andersoni. Because the disease is
relatively benign, the true incidence cannot be assessed. Many cases are never recognized by a physician, or, if cases are
recognized, the illness may not be recognized as CTF.
A 1974 ecologic study in Rocky Mountain National Park in north central Colorado identified the primary vertebrate host species
for the CTF virus as the least chipmunk (ie, Tamias minimus) and the golden-mantled ground squirrel (ie, Spermophilus
lateralis). Secondary hosts were the Uinta chipmunk (ie, Tamias umbrinus), Richardson ground squirrels (ie, Spermophilus
richardsonii), and the deer mouse (Peromyscus maniculatus). Larval and nymphal stages of D andersoni ticks were responsible
for transmission of CTF virus among rodents, and overwintering of the virus occurred in nymphal and adult D andersoni. Only
adult ticks transmit CTF virus to humans.
Rotavirus
The disease has been found on all continents and in all races, but its worldwide prevalence is not known. Since its discovery in
1973, rotavirus has been well documented as an important cause of diarrheal disease in infants and young children. Estimates
of the global disease burden of rotavirus diarrhea have been refined and suggest that mortality rates have not declined and that,
among hospitalized patients with diarrhea, the fraction of cases associated with rotavirus has increased in many countries. In
the United States, the estimated number of hospitalizations attributed to rotavirus has increased.
Although rotaviruses are found in high concentrations in the stools of children with diarrhea and are found less often in children
without diarrhea, the presence of rotavirus in the feces is not always associated with symptomatic disease. While asymptomatic
endemic rotavirus infections have been observed in newborns, isolation rates of rotavirus infection in asymptomatic infants and
children have been reported to be very low.
Morbidity and mortality data from selected studies conducted in the last 3 decades in Africa, Latin America, and Asia show that
morbidity rates are highest in infants aged 6-11 months, while the mortality rates are highest in infants and children aged 1 year.
In children younger than 5 years, the median incidence of diarrhea is 2.2 episodes per child per year for all studies.
Asymptomatic infections are common in infants younger than 6 months, the time during which protective maternal antibody
acquired passively by newborns should be present. Such neonatal infection does not prevent reinfection, but it may protect
against the development of severe disease during reinfection.
In temperate climates, rotaviruses are responsible for a large number of cases of diarrheal disease in the winter. The
seasonality of rotavirus disease is less apparent in tropical climates but is still more prevalent in the drier, cooler months.
The transmission of rotavirus infections is believed to be fecal-oral, with little evidence of airborne transmission. Adult contacts
may be infected, as evidenced by seroconversion, but they rarely exhibit symptoms, and the virus is detected infrequently in
their stools. A common source of infection is contact with children who are infected. However, epidemics of severe disease have
occurred in adults, especially in closed populations, as in a geriatric ward.
In one study, cases of asymptomatic infection and cases with mild symptoms were characteristic of rotavirus infections among
pediatric nurses, indicating that poor handwashing practices by the nursing staff may contribute to the spread of rotavirus
gastroenteritis in pediatric wards.[6]
Pathophysiology
Reovirus
Human volunteer studies have failed to demonstrate a clear cause-and-effect relationship between reoviruses and human
illness. Reoviruses have been associated with upper respiratory infections, fever, enteritis, and febrile exanthema in childhood.
Coloradotick fever
CTF virus can infect and replicate within both the KG-1a human progenitor cell line and human bone marrow progenitor cells.[7]
The finding of viral replication 16-48 hours after infection both with plaque assay and with electron microscopy followed by
pronounced cytopathic effects at 72-96 hours suggests that the virus is taken up by progenitor cells and diminishes both the
numbers and the functions of these cells. While progenitor cells may provide a hospitable environment for viral replication, the in
vitro data do not suggest that the cells serve as a long-term reservoir of virus. The CTF virus infects the bone marrow in the
initial phases of infection but does not persist. Viral replication occurs in the bone marrow, lymph nodes, spleen, heart, and liver
of rhesus monkeys but without histological abnormalities.
Human erythrocytes are known to carry the virus, and the virus has been shown to replicate in erythroblasts and reticulocytes of
infected mice. The viral presence in mature erythrocytes is postulated to be a result of replication of the virus in hematopoietic
erythrocyte precursor cells and simultaneous maturation of the infected immature cells rather than a result of direct entry and
replication of CTF virus in mature erythrocytes.
Rotavirus
After fecal-oral transmission of rotavirus, infection is initiated in the upper intestine and typically leads to a series of histologic
and physiologic changes. The incubation period is brief. Rotaviruses infect cells in the villi of the small intestine (gastric and
colonic mucosa are spared). They multiply in the cytoplasm of enterocytes and damage their transport mechanism.
One of the rotavirus-encoded proteins, NSP4, is a viral enterotoxin that induces secretion by triggering a signal transduction
pathway. Damaged cells may slough into the lumen of the intestine and release large quantities of viruses, which appear in
stool. Viral excretion usually lasts 2-12 days in healthy patients but may be prolonged in those with poor nutrition. Diarrhea
caused by rotaviruses may be due to impaired sodium and glucose absorption as damaged cells on villi are replaced by
nonabsorbing immature crypt cells. Three to 8 weeks may be necessary for normal function to be restored. Antibodies present
in the intestinal lumen have been shown to play a role in the passive protection of young animals.
Epidemiology
Frequency
United States
Reoviruses cause many inapparent infections; thus, estimating the true frequency of the infection is difficult. CTF is the most
common arboviral disease among people in the United States. It has been reported in at least 11 Western states in the United
States. Rotavirus infections account for 3.5 million cases of diarrhea each year and for 20 deaths that occur among children
younger than 5 years.
International
CTF has been reported from Alberta and British Colombia in Canada. In developing countries, 3-5 billion cases of gastroenteritis
occur each year. A significant proportion is believed to be caused by rotaviruses.
Mortality/Morbidity
Reovirus infection usually has a benign course. Little mortality is associated with reovirus infection.
CTF has a benign course, with an excellent prognosis. Rarely, CTF results in death, usually from hemorrhagic complications.
In developing countries, rotavirus accounts for 10-20% of gastroenteritis-associated deaths (ie, 5-10 million deaths each year).
Race
No clear racial predilection exists for reovirus, CTF virus, or rotavirus infection.
Sex
No clear sexual predilection exists for rotavirus, CTF virus, or rotavirus infection.
Age
A lower rate of acute or symptomatic infections is observed with reoviruses and rotaviruses with increasing age, which is a
consequence of the development of antibodies to these viruses. A single attack of CTF produces lifelong immunity.
Presentation
History
Reovirus
Reoviruses have been associated with upper respiratory infections, enteritis, fever, and febrile exanthema in childhood. In one
study in which volunteers were inoculated intranasally with each of the 3 reovirus serotypes, most infections were
asymptomatic, but illness associated with serotypes 1 and 2 included symptoms of the common cold. A few reports have been
made of isolation from the cerebrospinal fluid or brain of infants who have central nervous system disease. Some studies
suggest a relationship between reoviruses and neonatal biliary atresia or congenital hepatitis.
Neurologic disease
Reovirus infection in rodents, especially mice, has been used extensively as an experimental model system for studying the
pathogenesis of viral disease of the central nervous system.
Rare cases of reovirus-induced neurologic disease in humans, including encephalitis and meningitis, have been reported.
Reoviruses have been associated with neurologic illnesses in nonhumans, including hydrocephalus in monkeys, encephalitis in
dogs, and ataxia in cats.
For reoviruses to infect and injure the CNS, they must (1) enter the host, (2) spread from the site of entry to the CNS, (3) infect
cells within nervous tissue, (4) cause death of infected neuronal cells, and (5) successfully avoid the host's immune defenses.
A few isolated reports associating reoviruses with human disease of the CNS have been presented. In one report, reovirus
serotype 1 was isolated from stool specimens and postmortem brain tissue from a 10-month-old infant with encephalitis,
pneumonitis, myocarditis, and hepatitis.
A virus immunologically related to reovirus type 3 was isolated from the CSF and from postmortem samples of the brain and
spinal cord of a woman who died of encephalitis. In another case report, a previously healthy 3-month-old girl presented with
symptoms of meningitis, diarrhea, vomiting, and fever. Green monkey kidney cells inoculated with CSF revealed reoviruslike
particles on electron microscopy. RNA-gel electrophoresis, immunofluorescence, and virus neutralization have been used to
identify the pathogen isolated from CSF as reovirus serotype 1. The CSF isolate was also neutralized by reovirus serotype 1
antibodies.
Reovirus serotypes 1 and 3 produce unique and essentially nonoverlapping patterns of CNS injury in mice, and reovirus
serotype 2 produces encephalitis in suckling mice. Serotype 3 produces a neuronal infection that results in lethal encephalitis.
Serotype 1 appears not to infect neurons but instead causes ependymitis and hydrocephalus.
Upper respiratory illness
In the winter of 1957, Rosen and colleagues noted an outbreak of infection with reovirus serotype 1 in children in nursery school
in a welfare institution.[8] Illness was characterized by low-grade fever, rhinorrhea, and pharyngitis. The average duration of
fever was 2.2 days. In another study at the same institution during the winter of 1955-1956, 4 children with reovirus serotype 3
infection and illness were noted. One child had a temperature of 38.9°C, coryza, and tonsillitis; another child had fever (ie,
temperature 38.2°C), cough, and diarrhea; and 2 children only had coryza. During another reovirus serotype 3 outbreak in the
fall of 1957, all 6 infected infants had symptoms. Five children had mild fever, 5 had coryza, and 4 had diarrhea.
Other sporadic instances of similar mild upper respiratory illnesses have been described. In one study of volunteer trials in
young adults, reovirus serotype 1 infection was associated with malaise, rhinorrhea, cough, sneezing, pharyngitis, and
headache in some subjects, and a coldlike illness was observed in 37% of subjects in another trial. In both volunteer studies and
in natural infection, mild diarrhea occurred with the upper respiratory illness.
Pneumonia
Tillotson and Lerner (1967) reported on a 5-year-old girl who had extensive pneumonia and died after 15 days of illness.[9] This
child initially had fever, cough, rhinorrhea, and a generalized maculopapular rash. When admitted to the hospital on the 10th day
of illness, the child was cyanotic and in marked respiratory distress. A chest radiograph revealed a diffuse confluent pneumonia,
and reovirus type 3 was recovered from the lungs, adrenals, liver, spleen, kidney, (one) lymph node, heart, brain, and blood.
Joske and Keall (1964) noted a 10-month-old girl who died after a respiratory illness of 4 days' duration.[10] Reovirus type 1 was
recovered from the stool and brain of this child, and postmortem study revealed interstitial pneumonia, myocarditis, hepatitis,
and encephalitis.
El-Rai and Evans (1963) reported the case of an 18-year-old boy who had fever, nausea, vomiting, cough, and patchy
pneumonia.[11] He had serologic evidence of infection with reovirus type 1. Pneumonia has been noted in another child with
reovirus type 3 infection. Reovirus is a good pathogen in which to study mucosal immunity initiated in the respiratory tract.
Experiments using reovirus as a model pathogen in adult, newborn, and immunodeficient animals have been useful in
determining factors that mediate susceptibility and resistance to viral diseases, generation of specific immunity, and identification
of determinants that can regulate generation of specific mucosal immunity.
Because reovirus elicits immune responses after either enteric or respiratory infections, it can be used in studies concerning the
relationship between mucosal immune responses at these sites. In addition, reovirus infection provides an opportunity to study
molecular and cellular events that regulate the induction and expression of mucosal immune responses.
Reovirus might prove to be an effective vehicle for delivery of mucosal vaccines. In conclusion, much of the advancement in
current knowledge of mucosal immune responses has been facilitated by studies of respiratory and enteric reovirus infection,
and reovirus likely will continue to be used as a probe to understand the function and regulation of one of the most important
defenses, mucosal immunity.
Bronchiolitis obliterans-organizing pneumonia
Bronchiolitis obliterans-organizing pneumonia (BOOP) is a term that was first applied in 1985 to describe a long-observed but
unclassified pattern of acute lung injury. BOOP lesions are characterized by fibrous extensions into the alveolar spaces in
association with a peribronchiolar organizing pneumonia. Although BOOP can be associated with numerous documented
pulmonary insults, many cases are not associated with known causes and thus are classified as idiopathic. In one study, CBA/J
mice infected with reovirus serotype 1 developed BOOP lesions. These lesions closely resembled lesions observed in humans
and developed in a well-defined temporal sequence that proceeded from initial peribronchiolar inflammatory lesions to
characteristic fibrotic cellular BOOP lesions over a 3-week period.[12]
Gastrointestinal manifestations
Mild diarrhea has been noted both in association with upper respiratory illness and as an isolated event. Because reovirus type
3 consistently produces steatorrhea in mice, this clinical manifestation has been sought and noted in illnesses of children.
Patients have been reported with hepatitis and encephalitis.
Extrahepatic biliary atresia (EHBA) and choledochal cysts (CDCs) are important causes of obstructive jaundice in pediatric
patients. Viruses in general, and reoviruses in particular, have long been considered as possible etiologic agents responsible for
inciting the inflammatory process that leads to these infantile obstructive cholangiopathies.
In one study, hepatic and biliary tissues were obtained at the time of liver biopsy or surgical procedure from 23 patients with
EHBA, 9 patients with CDC, 33 patients with other hepatobiliary diseases, and at autopsy from 17 patients who died without
known liver or biliary disease. Reovirus RNA was detected in hepatic and/or biliary tissue from 55% of patients with EHBA and
78% of patients with CDC. Reovirus RNA was also found in extracts of hepatic and/or biliary tissue from 21% of patients with
other hepatobiliary diseases and in 12% of autopsy cases. The prevalence of reovirus RNA in tissues from patients with EHBA
and CDC was significantly greater than that in patients with other hepatobiliary diseases. A sensitive and specific reverse
transcriptase–polymerase chain reaction (RT-PCR) technique was used to amplify a portion of the reovirus 1 gene segment
from extracts of liver and/or biliary tissues.[13]
Diabetes mellitus
Reovirus may be involved in the pathogenesis of type 1 diabetes mellitus by inducing beta cell–specific autoimmunity, with or
without infection of the beta cells.[14]
Colorado tick fever
The incubation period is 3-6 days. The clinical picture is characterized by the sudden onset of chilliness, variable fever, and
headache with retro-orbital pain, generalized aches (especially of the back and extremities), malaise, nausea, and, occasionally,
vomiting. In most cases, the severity of symptoms reaches the maximum intensity within a few hours. The fever is variable, and
temperature may be as high as 104°F within the first 24 hours of symptoms. A rash is generally absent but may be noted on
occasion and can be macular, maculopapular, or petechial. No characteristic distribution is observed.
The single most important laboratory finding that confirms diagnosis is a moderate-to-marked leukopenia, which is invariably
present. On the first day of illness, the white blood cell count may be within the reference range, but, usually by the third day, the
white cell count has decreased to 4000 cells/μL or lower, with a relative lymphocytosis. The leukopenia is generally most
profound during the second bout of fever. In CTF, mononuclear cell production of granulocyte colony-stimulating factor is
decreased, and an increase in circulating granulopoietic inhibitory factors is found in the serum of such patients.
CTF usually has a biphasic course with 2 bouts of fever, each of which lasts 2-3 days, separated by a remission of
approximately equal duration. This produces the so-called saddle-backed temperature curve. On occasion, the patient may
remain febrile during the entire course of the disease, while, in other instances, a third or even fourth exacerbation of fever may
occur. The usual duration of the febrile period is approximately 1 week but may be longer. In most cases, the febrile period is
followed by several days of moderate-to-marked weakness and malaise. Convalescence may be prolonged. Mild and subclinical
infections occur, and one infection usually produces lifelong immunity.
Although CTF usually has a benign course and carries an excellent prognosis, in a few cases, complications such as
encephalitis, aseptic meningitis, and hemorrhage have been reported. Other associated syndromes include pericarditis,
epididymoorchitis, a rheumatic fever–like syndrome, and atypical pneumonitis. The association of hepatitis with CTF also has
been described. Saddle-backed fever is absent in as many as 52-58% of patients.
Circulating immune complexes may be the cause of the second phase of illness that many patients experience, as well as some
of the unusual manifestations of the disease such as hepatitis, epididymoorchitis, rheumatic fever–like illness, and atypical
pneumonitis. The virus is easily isolated from the erythrocytes of most affected patients and from the cerebrospinal fluid of those
with central nervous system involvement. Viral replication occurs in the bone marrow, lymph nodes, spleen, heart, and liver of
rhesus monkeys but without histological abnormalities. Human erythrocytes are shown to carry the virus, and the virus has been
shown to replicate in erythroblasts and reticulocytes of infected mice. Viral presence in mature erythrocytes is postulated to be
the result of replication of the virus in hematopoietic erythrocyte precursor cells followed by maturation of the infected cells
rather than the result of direct entry and replication of CTF virus in mature erythrocytes.
The early course of RMSF and CTF share many features: a history of tick bite, abrupt onset, fever, chills, headache, myalgia,
and photophobia. However, later in the course, the distinctive features of these illnesses emerge. The disappearance of
symptoms after 2-3 days strongly favors CTF, as does the appearance of marked leukopenia. Rash can occur in both diseases,
although it is infrequent in CTF and is usually present in RMSF. The rash of RMSF may be distinguished by its centrifugal
distribution, involvement of the palms and soles, and progression from a petechial stage to a purpuric stage.
Edema, pneumonitis, and involvement of other organs are observed only in RMSF and reflect the diffuse vasculitis of this
disease. Bleeding secondary to thrombocytopenia can be a serious complication of CTF. The acute phase of CTF typically lasts
5-10 days and is followed by convalescence, which may be protracted, especially in adults. Although the incubation time from
tick exposure to the onset of symptoms is about 4 days, the range is from less than 1 day to 14 days.
Rotavirus
Infants and young children most commonly have fever, vomiting, diarrhea, and (occasionally) dehydration. Vomiting, usually
short-lived, can occur before or after the onset of diarrhea. Symptoms of an apparent respiratory infection may be present. The
patient's stools can be watery, green or yellow, and not obviously bloody. Stools rarely contain mucus and number as many as
10 per day. In most cases, diarrhea lessens soon after admission and, in only a few cases, persists longer than 3-4 days.
The association of HRV, gastroenteritis, and upper respiratory tract symptoms has been noted frequently. Santosham et al
(1983) detected HRV in the respiratory secretions of 4 infants with enzyme-linked immunoassay (ELISA).[15]
The low rate of severe gastroenteritis observed in newborns infected with rotavirus possibly is a function of relatively low
intestinal concentration of trypsin and other proteolytic enzymes required for the development of diarrheal disease. In one study,
rotavirus was detected in the stools of 5 children who, over a 3-week period, developed sudden infant death syndrome (SIDS).
While none of the children had acute gastroenteritis, 4 of the 5 had acute upper respiratory infections.
Rotavirus was identified in tracheal aspirates from 2 of the infants. Extensive investigations failed to reveal the presence of any
other virus or toxins in specimens obtained from the 5 children with SIDS. Rotavirus was not found in the stool specimens
obtained from a control group of 36 infants, including 6 who died of causes other than SIDS.[16]
An association of rotavirus with aseptic meningitis and Kawasaki syndrome has been reported.[17] In adults, symptoms are
generally mild and are associated with a low density of viral shedding compared with that of pediatric diarrhea, in which the
density of viral shedding in stool generally is 10-fold higher. Preexisting partial immunity of adults might mask overt symptoms of
diarrhea. Asymptomatic shedders of rotavirus might serve as a reservoir for disease transmission, particularly to susceptible
children.
Rotavirus can also cause gastroenteritis in adults not in contact with sick children. The main difficulty in studying rotavirus
gastroenteritis in adults is that symptoms are often minimal and the individual does not seek medical advice. Asymptomatic
rotaviral infection is uncommon, and the association between rotavirus and diarrhea is not necessarily an etiologic one.
Consequently, recovery of rotavirus from feces is of little diagnostic significance because it does not differentiate between
rotavirus-induced and rotavirus-associated diarrhea.
Rotavirus also has been reported as an agent of travelers' diarrhea in adults.[18] The coexistence of respiratory symptoms in
several patients suggests that the virus might infect the respiratory epithelium as well, but no proof exists for HRV infection
outside of the gut.
Rotavirus infection in immunocompromised adults can have a variable course, from no symptoms to severe and sustained
infection.
The extraintestinal spread of the virus may occur through blood because viremia has been documented occasionally in animals
and humans.[19] Nevertheless, the questions of how common viremia is in immunocompetent children and whether it is
associated with extraintestinal manifestations remain unsolved.
Physical
Reovirus
Reoviruses usually cause mild physical illness. In rare cases when complications (eg, pneumonia, encephalitis, meningitis)
occur, associated physical findings may be observed.
Coloradotick fever
The triad of high fever, severe myalgia, and headache is typical but not specific. Tachycardia, flushed facies, and variable
degrees of conjunctival and pharyngeal injection may be present. Occasionally, the spleen is palpable. In some cases, evidence
of central nervous system involvement, with clouding of the sensorium, neck stiffness, and vomiting, may be present. Rarely,
encephalitis, aseptic meningitis[20] , and hemorrhage have been reported. Other associated syndromes include pericarditis,
epididymo-orchitis, rheumatic fever syndrome, and atypical pneumonitis. The association of hepatitis with CTF also has been
described. In these cases, the related physical findings can be present.
Rotavirus
Physical findings in rotavirus gastroenteritis depend on the severity of dehydration. Findings characteristic of shock (eg,
tachycardia, hypotension, clammy skin, weak pulse) can be present in severe disease.
Causes
See Epidemiology and Pathophysiology.
DDx
Differential Diagnoses
Bacterial Gastroenteritis
Epstein-Barr Virus (EBV) Infectious Mononucleosis (Mono)
Influenza
Rocky Mountain Spotted Fever (RMSF)
Viral Gastroenteritis
Workup
Workup
Laboratory Studies
Routine laboratory tests, such as CBC count, electrolytes, and liver profile, may be needed.
Reovirus
Reoviruses have been shown to replicate in various cell culture types used by laboratories for general viral culture, but these
agents are only rarely isolated from clinical samples.
Paired acute- and convalescent-phase serum samples can be used to detect seroconversion via hemagglutination inhibition,
complement fixation, or virus neutralization.
Colorado tick fever
Diagnosis of CTF in humans has been established most reliably by isolation of the virus from the erythrocyte fraction of whole
blood or by demonstrating the presence of viral antigen in the erythrocytes via the direct fluorescent-antibody technique. The
CTF virus has been shown to persist in erythrocytes of patients for as long as 120 days. The virus has been found in
cerebrospinal fluid in people with no apparent encephalitis or meningitic involvement. Whole blood specimens shipped
unrefrigerated to the laboratory by surface mail are satisfactory for virus isolation. However, virus isolation and identification
takes 1-2 weeks from the time of receipt of the specimen. The fluorescent-antibody technique requires special equipment that
some laboratories do not possess, and interpretation of the results is subjective.
Detection of antibody is also an adequate tool for diagnosing infection with this virus, but dependence on this method has
several drawbacks. Various serologic procedures, such as neutralization tests in suckling and weanling mice, tissue culture
neutralization, plaque-reduction methods, complement fixation, and direct immunofluorescence, have been used. Complement
fixation antibody titers are low usually, and about 25% of infected individuals do not develop a complement fixation antibody
response.
To demonstrate a diagnostically significant change in antibody titer, sera must be obtained at least 1 week after onset and again
3-4 weeks later. The specific neutralizing and complement fixing antibodies appear in the blood between the eighth and 14th
days of the illness; neutralizing antibodies have been demonstrated to be present for many years. Blood from acute- or
convalescent-phase samples can be inoculated into suckling mice or susceptible cell cultures (eg, baby hamster kidney [BHK]
or Vero cells).
PCR techniques have been developed that allow the diagnosis to be established from the first day of symptoms.
Rotavirus
Rotaviruses are fastidious agents to culture and cannot be detected via routine viral isolation techniques. Most HRVs can be
cultivated if pretreated with the proteolytic enzyme trypsin and if low levels of trypsin are included in the tissue culture medium.
This cleaves an outer capsid protein and facilitates uncoating.
Direct electron microscopy, although the least sensitive technique, affords by far the most rapid method for detecting fecal
viruses and has proven to be an especially useful diagnostic and teaching tool when used to test the first available stool sample
from acutely ill patients with diarrhea during periods of rotavirus activity.
Direct EIA and on-grid immunoelectron microscopy (IEM) techniques are approximately equivalent in sensitivity and reliability.
Compared with the conventional electron microscopy method, both techniques are about 9 times more sensitive in detecting
purified SA-11 (simian rotavirus) and 3 times more sensitive in detecting HRV in crude stool samples. The IEM technique is
presently the best method for detecting all of the known gastroenteritis viruses, especially in rectal swab specimens, but, with
most stool specimens, IEM takes hours longer than direct electron microscopy to provide the same diagnostic result.
The Rotazyme test is a useful tool in the diagnosis of HRV gastroenteritis. Testing should be performed early in the course of the
illness. The maximum number of viral particles is found in the stool of infants in the first few days of illness, especially between
the second and fifth days. Excretion generally continues for as long as 8 days, with some reports of excretion as late as 23 days
and even later in the immunosuppressed population. Because of the decreasing concentrations of viral particles excreted as the
patient improves, testing after 23 days may fail to detect viral antigen. Because rotavirus infects the epithelial cells of small
intestinal villi, mucosal gut antibodies are the most reliable indicators of immune response following natural rotavirus infection or
rotavirus vaccination. In one study, saliva was used as a marker of intestinal immune response following natural rotavirus
diarrhea in infants, the reasoning being that primed immunocompetent cells from the gut migrate to distant mucosal sites where
they produce antibodies.[21]
Quantitative real-time PCR can also be used in the diagnosis of rotavirus, along with other bacteria and viruses in a multiplex
platform.[22]
Usually, no abnormalities of peripheral white blood cell count or significantly elevated numbers of polymorphonuclear leukocytes
or immature forms are found. These cells may have higher alanine aminotransferase (ALT) and aspartate aminotransferase
(AST) levels.
Hypophosphatemia may be present in as many as 50% of cases of rotavirus gastroenteritis. Uric acid levels above 10 mg/dL
also can be present. Most patients have mild compensated metabolic acidosis with decreased plasma bicarbonate levels.
Treatment
Medical Care
Reovirus
No specific treatment or prevention measures have been recommended for reovirus infections in humans because of the lack of
definitive association with disease.
Colorado tick fever
Ribavirin may merit consideration in the appropriate clinical setting. Bed rest, fluids, and antipyretics are recommended as
symptomatic therapy.
Rotavirus
Treatment of rotavirus gastroenteritis consists of restoring the fluid loss in dehydrated patients. Emphasis has shifted from
intravenous to oral rehydration using glucose electrolyte solutions. The solution recommended by the World Health Organization
(WHO) contains 30 mEq/L of sodium, 30 mEq/L of potassium, and 30 mEq of bicarbonate. In cases of severe dehydration,
intravenous solutions can be used. Antimotility drugs are rarely indicated in children with gastroenteritis because the potential
risks outweigh the benefits.
Diet
Start feeding within 24 hours of rotavirus gastroenteritis. This includes breast milk or diluted formula or milk in infants and
lactose-free, carbohydrate-rich foods in older children. Fruit juice and soft drinks are not recommended because of their low
sodium and high glucose concentrations.
Medication
Medication Summary
No specific medications are used for treatment of diseases caused by Reoviridae family.
Follow-up
Deterrence/Prevention
Reovirus
No specific treatment or prevention measures are recommended for reovirus infections in humans because of the lack of
definitive association with disease. Vaccine preparations are available for veterinary use.
Colorado tick fever
CTF is best prevented by avoiding contact with the wood tick. This may be achieved by wearing suitable clothing to decrease
the possibility of an infected tick becoming attached to the body. Instruct patients and family members to inspect the scalp and
neck and the sleeve, belt, trouser, and sock line areas carefully for ticks several times each day and to remove any ticks that
may be found to prevent them from becoming imbedded in the skin.
Repellent can be sprayed on clothing or applied to exposed skin in adults. Remind patients and family members to tuck long
pants into socks, to wear shirts tucked in, and to inspect clothing and skin frequently for attached ticks. Identifying ticks on light-
colored clothing is easier. Persons with documented CTF should be prohibited from blood donation until the viremia, which often
is prolonged, has cleared.
Education is the best means by far of preventing the disease. Periodically remind the public of the clinical features of CTF and
the ticks that transmit the causative agents. Because of the generally benign nature of the disease, attempts at active
immunization do not appear to be indicated, and extensive specific measures to rid any large area of the United States of the
wood tick do not appear to be warranted.
Rotavirus
Rotavirus typically infects children in the first 3 years of life during epidemics that occur in the winter in temperate climates. In
developed countries with ready access to medical care and careful attention to oral and intravenous rehydration, fatalities are
relatively rare, but rotavirus illness is still an important cause of morbidity. In developing countries, the impact of the disease is
much more striking, with estimates that rotavirus may be the leading cause of childhood mortality in many countries.
In view of the fecal-oral route of transmission, wastewater treatment and sanitation are significant control measures.
Responses to the vaccine are generally assessed by evaluating the rise in serum antibody levels. However, several rotavirus
vaccine trials indicate that clinical efficacy rates are higher than seroconversion rates, suggesting that serum antibodies are not
sensitive enough indicators of immune responses and that assessment of local immunity may prove more reliable.
Studies addressing the role of serum antibody as a predictor of susceptibility to infection and illness have yielded conflicting
results because monitoring of serum antibody responses may underestimate mucosal antibody by as much as 200%.
Precedents for using animal rotavirus strains as vaccine candidates include (1) the antigenic relatedness between human and
animal rotaviruses and (2) evidence for the stimulation of heterologous protective immunity using one strain of rotavirus as an
immunogen. For example, calves infected in utero with calf rotavirus developed resistance to challenge with HRV.
A rhesus rotavirus-tetravalent vaccine (RRV-TV, Rotashield) was licensed for use in the United States in August 1998. The
vaccine consists of a quadrivalent formulation incorporating the VP7 neutralization specificity of each of the 4 clinically important
serotypes with the attenuation phenotype of rhesus rotavirus.
The rhesus rotavirus–based quadrivalent vaccine was very successful in preventing severe rotavirus diarrhea in 2 trials in the
United States and in one in Finland, with protection rates of 80-91%. In developing countries, its efficacy has been less
impressive.
In Peru and Brazil, the efficacy of RRV-TV afforded only 20% and 35% protection respectively for any rotavirus gastroenteritis
and 50-60% protection for severe rotavirus gastroenteritis. A febrile reaction occurred in about 30% of those vaccinated in
Finland. Although most reactions were mild and clinically insignificant, the finding is an important part of the total clinical profile
of the vaccine. In a United States multicenter trial, only 7% of vaccine recipients and 4% of placebo recipients had fever during
the 5 days after the first vaccination. On July 16, 1999, the Centers for Disease Control and Prevention recommended that
health care providers suspend use of the licensed RRV-TV (RotaShield, Wyeth Laboratories, Inc, Marietta, Pennsylvania) in
response to 15 cases of intussusception.[23]
The risk of intussusception following RotaShield immunization is estimated to be 1 in 10,000-32,000.[24] The risk is highest
during the 3-14 days following receipt of the first dose of vaccine. Infants older than 3 months at the time of the first dose of
vaccine are at increased risk of intussusception. Although debate continues surrounding the exact quantitation of risk of
intussusception, it is accepted as a rare adverse event.
Several rotavirus vaccines are now marketed in the United States. The orally administered live-virus vaccines exhibit similar
safety characteristics. RotaTeq is a pentavalent vaccine that contains 5 live reassortant rotaviruses and is administered as a 3-
dose regimen against G1, G2, G3, and G4 serotypes, the 4 most common rotavirus group A serotypes. RotaTeq also contains
attachment protein P1A (genotype P[8]). Rotarix protects against rotavirus gastroenteritis caused by G1, G3, G4, and G9 strains
and is administered as a 2-dose series in infants aged 6-24 weeks.
Complications
Reovirus
Rare cases of reovirus-induced neurologic disease in humans, including encephalitis and meningitis, have been reported. A 10-
month-old infant with encephalitis, pneumonitis, myocarditis, and hepatitis was reported in whom reovirus serotype 1 was
isolated from stool specimens and postmortem brain tissue. Tillotson and Lerner (1967) reported a 5-year-old girl who had
extensive pneumonia and died after 15 days of illness.[9]
Joske and associates (1964) noted a 10-month-old girl who died after a respiratory illness of 4 days' duration.[10] Reovirus type
1 was recovered from the stool and brain of this child, and postmortem study revealed interstitial pneumonia, myocarditis,
hepatitis, and encephalitis.
Colorado tick fever
In a few cases, complications such as encephalitis, aseptic meningitis, and hemorrhage have been reported. Other associated
syndromes include pericarditis, epididymoorchitis, rheumatic fever syndrome, and atypical pneumonitis. The association of
hepatitis with CTF also has been described.
Rotavirus
Rotavirus infections are associated with aseptic meningitis, necrotizing enterocolitis, acute myositis, hepatic abscess,
pneumonia, Kawasaki disease[17] , SIDS[25] , and Crohn disease.
Prognosis
Reovirus and CTF infections
Reovirus and CTF infections are usually benign diseases with excellent prognosis.
Rotavirus
In developed countries with ready access to medical care and careful attention to oral and intravenous rehydration, fatalities are
relatively rare, but rotavirus illness is still an important cause of morbidity.
In developing countries, the impact of the disease is much more striking, with estimates that it may be the leading cause of
childhood mortality in many countries.
Patient Education
Because reovirus and rotavirus infections occur by fecal-oral transmission, wastewater treatment and sanitation are significant
control measures.
Colorado tick fever: Education is by far the best means of preventing the disease. The public should be periodically reminded of
the clinical features of CTF and the ticks that transmit the causative agents. Repellents can be sprayed on clothing or applied to
exposed skin. Remind patients and family members to tuck long pants into socks, to wear shirts tucked in, and to inspect
clothing and skin frequently for attached ticks. Identifying ticks on light-colored clothing is easier.
For excellent patient education resources, visit eMedicineHealth's Children's Health Center. Also, see eMedicineHealth's patient
education articles Ticks and Sudden Infant Death Syndrome (SIDS).
Contributor Information and Disclosures
Author
Andrew Stevenson Joel Chandranesan, MBBS Assistant Professor of Medicine and Infectious Diseases, Associate Program
Director, Infectious Diseases Fellowship Program, Louisiana State University School of Medicine in Shreveport
Andrew Stevenson Joel Chandranesan, MBBS is a member of the following medical societies: Infectious Diseases Society of
America, Massachusetts Infectious Diseases Society, Massachusetts Medical Society
Disclosure: Nothing to disclose.
Specialty Editor Board
Francisco Talavera, PharmD, PhD Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy;
Editor-in-Chief, Medscape Drug Reference
Disclosure: Received salary from Medscape for employment. for: Medscape.
Aaron Glatt, MD Chairman, Department of Medicine, Chief, Division of Infectious Diseases, Hospital Epidemiologist, South
Nassau Communities Hospital
Aaron Glatt, MD is a member of the following medical societies: American Association for Physician Leadership, American
College of Chest Physicians, American College of Physicians, American College of Physicians-American Society of Internal
Medicine, American Medical Association, American Society for Microbiology, American Thoracic Society, American Venereal
Disease Association, Infectious Diseases Society of America, International AIDS Society, Society for Healthcare Epidemiology
of America
Chief Editor
Mark R Wallace, MD, FACP, FIDSA Clinical Professor of Medicine, Florida State University College of Medicine; Clinical
Professor of Medicine, University of Central Florida College of Medicine
Mark R Wallace, MD, FACP, FIDSA is a member of the following medical societies: American College of Physicians, American
Medical Association, American Society for Microbiology, Infectious Diseases Society of America, International AIDS Society,
Florida Infectious Diseases Society
Additional Contributors
John W King, MD Professor of Medicine, Chief, Section of Infectious Diseases, Director, Viral Therapeutics Clinics for Hepatitis,
Louisiana State University Health Sciences Center; Consultant in Infectious Diseases, Overton Brooks Veterans Affairs Medical
Center
John W King, MD is a member of the following medical societies: American Association for the Advancement of Science,
American College of Physicians, American Federation for Medical Research, Association of Subspecialty Professors, American
Society for Microbiology, Infectious Diseases Society of America, Sigma Xi
Gholamreza Rasouli, MD
Gholamreza Rasouli, MD is a member of the following medical societies: American College of Physicians-American Society of
Internal Medicine, American Medical Association
Acknowledgements
Wesley W Emmons, MD, FACP Assistant Professor, Department of Medicine, Thomas Jefferson University; Consulting Staff,
Infectious Diseases Section, Department of Internal Medicine, Christiana Care, Newark, DE
Wesley W Emmons, MD, FACP is a member of the following medical societies: American College of Physicians, American
Medical Association, American Society of Tropical Medicine and Hygiene, Infectious Diseases Society of America, and
International AIDS Society
References
1. Fukuhara H, Ino Y, Todo T. Oncolytic virus therapy: A new era of cancer treatment at dawn. Cancer Sci. 2016 Oct;107(10):1373-
1379.
2. Carroll K, Hastings C, Miller CL. Amino acids 78 and 79 of Mammalian Orthoreovirus protein µNS are necessary for stress granule
localization, core protein ?2 interaction, and de novo virus replication. Virology. 2014 Jan 5. 448:133-45. [Medline]. [Full Text].
3. Steyer A, Gutiérrez-Aguire I, Kolenc M, Koren S, Kutnjak D, Pokorn M, et al. High similarity of novel orthoreovirus detected in a child
hospitalized with acute gastroenteritis to mammalian orthoreoviruses found in bats in Europe. J Clin Microbiol. 2013 Nov.
51(11):3818-25. [Medline]. [Full Text].
4. Boehme KW, Lai CM, Dermody TS. Mechanisms of reovirus bloodstream dissemination. Adv Virus Res. 2013. 87:1-35. [Medline].
5. Yendell SJ, Fischer M, Staples JE. Colorado tick fever in the United States, 2002-2012. Vector Borne Zoonotic Dis. 2015
May;15(5):311-6.
6. Hjelt K, Grauballe PC, Henriksen L, Krasilnikoff PA. Rotavirus infections among the staff of a general paediatric department. Acta
Paediatr Scand. 1985 Jul. 74(4):617-8. [Medline].
7. Philipp CS, Callaway C, Chu MC, Huang GH, Monath TP, Trent D, et al. Replication of Colorado tick fever virus within human
hematopoietic progenitor cells. J Virol. 1993 Apr. 67(4):2389-95. [Medline].
8. Rosen L, Hovis JF, Mastrota FM. An outbreak of infection with type 1 reovirus among children in an institution. Am J Hyg. 1960.
71:266-74.
9. Tillotson JR, Lerner AM. Reovirus type 3 associated with fatal pneumonia. N Engl J Med. 1967 May 11. 276(19):1060-3. [Medline].
10. Joske RA, Keall DD, Leak PJ, Stanley NF, Walters MN. Hepatitis-encephalitis in humans with reovirus infection. Arch Intern Med.
1964 Jun. 113:811-6. [Medline].
11. El-Rai FM, Evans AS. Reovirus infections in children and young adults. Arch Environ Health. 1963 Dec. 7:700-4. [Medline].
12. Bellum SC, Dove D, Harley RA, Greene WB, Judson MA, London L, et al. Respiratory reovirus 1/L induction of intraluminal fibrosis.
A model for the study of bronchiolitis obliterans organizing pneumonia. Am J Pathol. 1997 Jun. 150(6):2243-54. [Medline].
13. Joensuu J, Koskenniemi E, Pang XL, Vesikari T. Randomised placebo-controlled trial of rhesus-human reassortant rotavirus vaccine
for prevention of severe rotavirus gastroenteritis. Lancet. 1997 Oct 25. 350(9086):1205-9. [Medline].
14. Jun HS, Yoon JW. A new look at viruses in type 1 diabetes [reprint]. ILAR J. 2004. 45(3):349-74.
15. Santosham M, Yolken RH, Quiroz E, Dillman L, Oro G, Reeves WC, et al. Detection of rotavirus in respiratory secretions of children
with pneumonia. J Pediatr. 1983 Oct. 103(4):583-5. [Medline].
16. Yolken R, Murphy M. Sudden infant death syndrome associated with rotavirus infection. J Med Virol. 1982. 10(4):291-6. [Medline].
17. Matsuno S, Utagawa E, Sugiura A. Association of rotavirus infection with Kawasaki syndrome. J Infect Dis. 1983 Jul. 148(1):177.
[Medline].
18. Vollet JJ, Ericsson CD, Gibson G, Pickering LK, DuPont HL, Kohl S, et al. Human rotavirus in an adult population with travelers'
diarrhea and its relationship to the location of food consumption. J Med Virol. 1979. 4(2):81-7. [Medline].
19. Chiappini E, Azzari C, Moriondo M, Galli L, de Martino M. Viraemia is a common finding in immunocompetent children with rotavirus
infection. J Med Virol. 2005 Jun. 76(2):265-7. [Medline].
20. Wong CJ, Price Z, Bruckner DA. Aseptic meningitis in an infant with rotavirus gastroenteritis. Pediatr Infect Dis. 1984 May-Jun.
3(3):244-6. [Medline].
21. Aiyar J, Bhan MK, Bhandari N, Kumar R, Raj P, Sazawal S. Rotavirus-specific antibody response in saliva of infants with rotavirus
diarrhea. J Infect Dis. 1990 Dec. 162(6):1383-4. [Medline].
22. Liu J et al. Use of quantitative molecular diagnostic methods to identify causes of diarrhoea in children: a reanalysis of the GEMS
case-control study. Lancet. 2016 Sep 24;388(10051):1291-301.
23. Centers for Disease Control and Prevention (CDC. Suspension of rotavirus vaccine after reports of intussusception--United States,
1999. MMWR Morb Mortal Wkly Rep. 2004 Sep 3. 53(34):786-9. [Medline].
24. Bines JE. Rotavirus vaccines and intussusception risk. Curr Opin Gastroenterol. 2005 Jan. 21(1):20-5. [Medline].
25. Yang WQ, Senger DL, Lun XQ, Muzik H, Shi ZQ, Dyck RH, et al. Reovirus as an experimental therapeutic for brain and
leptomeningeal metastases from breast cancer. Gene Ther. 2004 Nov. 11(21):1579-89. [Medline].
26. Norman KL, Lee PW. Reovirus as a novel oncolytic agent. J Clin Invest. 2000 Apr. 105(8):1035-8. [Medline].
27. Clarke P, Debiasi RL, Goody R, Hoyt CC, Richardson-Burns S, Tyler KL. Mechanisms of reovirus-induced cell death and tissue
injury: role of apoptosis and virus-induced perturbation of host-cell signaling and transcription factor activation. Viral Immunol. 2005.
18(1):89-115. [Medline].
28. Kim M, Chung YH, Johnson RN. Reovirus and tumor oncolysis. J Microbiol. 06/2007. 45(3):187-92. [Medline].
29. Coulson BS, Grimwood K, Hudson IL, Barnes GL, Bishop RF. Role of coproantibody in clinical protection of children during
reinfection with rotavirus. J Clin Microbiol. 1992 Jul. 30(7):1678-84. [Medline].
30. Adelberg EA, Brooks GF, Jawetz E, et al. Medical Microbiology. 19th ed. Norwalk, Conn: Appleton & Lange; 1991. 460-468.
31. Andersen RD, Entringer MA, Robinson WA. Virus-induced leukopenia: Colorado tick fever as a human model. J Infect Dis. 1985
Mar. 151(3):449-53. [Medline].
32. Anderson EJ, Weber SG. Rotavirus infection in adults. Lancet Infect Dis. 2004 Feb. 4(2):91-9. [Medline].
33. Armstrong D, Cohen J. Infectious Diseases. St. Louis, Mo: Mosby Inc; 1999. Vol 2:
34. Bishop RF, Barnes GL, Cipriani E, Lund JS. Clinical immunity after neonatal rotavirus infection. A prospective longitudinal study in
young children. N Engl J Med. 1983 Jul 14. 309(2):72-6. [Medline].
35. Brandt CD, Kim HW, Rodriguez WJ, Thomas L, Yolken RH, Arrobio JO, et al. Comparison of direct electron microscopy, immune
electron microscopy, and rotavirus enzyme-linked immunosorbent assay for detection of gastroenteritis viruses in children. J Clin
Microbiol. 1981 May. 13(5):976-81. [Medline].
36. Burgdorfer W. Tick-borne diseases in the United States: Rocky Mountain spotted fever and Colorado tick fever. A review. Acta Trop.
1977 Jun. 34(2):103-26. [Medline].
37. Carr ME, McKendrick GD, Spyridakis T. The clinical features of infantile gastroenteritis due to rotavirus. Scand J Infect Dis. 1976.
8(4):241-3. [Medline].
38. Champsaur H, Questiaux E, Prevot J, Henry-Amar M, Goldszmidt D, Bourjouane M, et al. Rotavirus carriage, asymptomatic
infection, and disease in the first two years of life. I. Virus shedding. J Infect Dis. 1984 May. 149(5):667-74. [Medline].
39. Christy C, Madore HP, Pichichero ME, Gala C, Pincus P, Vosefski D, et al. Field trial of rhesus rotavirus vaccine in infants. Pediatr
Infect Dis J. 1988 Sep. 7(9):645-50. [Medline].
40. Chua KB, Voon K, Yu M, Keniscope C, Abdul Rasid K, Wang LF. Investigation of a potential zoonotic transmission of orthoreovirus
associated with acute influenza-like illness in an adult patient. PLoS One. 2011. 6(10):e25434. [Medline]. [Full Text].
41. Clark HF, Offit PA. Vaccines for rotavirus gastroenteritis universally needed for infants. Pediatr Ann. 2004 Aug. 33(8):536-43.
[Medline].
42. Davidson GP, Hogg RJ, Kirubakaran CP. Serum and intestinal immune response to rotavirus enteritis in children. Infect Immun. 1983
May. 40(2):447-52. [Medline].
43. Elliott EJ, Dalby-Payne JR. 2. Acute infectious diarrhoea and dehydration in children. Med J Aust. 2004 Nov 15. 181(10):565-70.
[Medline].
44. Emmons RW, Lennette EH. Immunofluorescent staining in the laboratory diagnosis of Colorado tick fever. J Lab Clin Med. 1966
Dec. 68(6):923-9. [Medline].
45. Feigin RD, Cherry JD. In: Textbook of Pediatric Infectious Diseases. Vol 2. Philadelphia, Pa: WB Saunders Co; 1998. 1897-1922.
46. Fraser CH, Schiff DW. Colorado Tick Fever Encephalitis. Pediatrics. 1962. 29:187-190.
47. Gorbach SL, Bartlett JG, Neil RB. Infectious Diseases. 2nd ed. Philadelphia, Pa: WB Saunders Co; 1998. 2193-9.
48. Gothefors L, Wadell G, Juto P, Taniguchi K, Kapikian AZ, Glass RI. Prolonged efficacy of rhesus rotavirus vaccine in Swedish
children. J Infect Dis. 1989 Apr. 159(4):753-7. [Medline].
49. Gouvea V, Glass RI, Woods P, Taniguchi K, Clark HF, Forrester B, et al. Polymerase chain reaction amplification and typing of
rotavirus nucleic acid from stool specimens. J Clin Microbiol. 1990 Feb. 28(2):276-82. [Medline].
50. Grimwood K, Lund JC, Coulson BS, Hudson IL, Bishop RF, Barnes GL. Comparison of serum and mucosal antibody responses
following severe acute rotavirus gastroenteritis in young children. J Clin Microbiol. 1988 Apr. 26(4):732-8. [Medline].
51. Johnson AJ, Karabatsos N, Lanciotti RS. Detection of Colorado tick fever virus by using reverse transcriptase PCR and application
of the technique in laboratory diagnosis. J Clin Microbiol. 1997 May. 35(5):1203-8. [Medline].
52. Kapikian AZ, Kim HW, Wyatt RG, Cline WL, Arrobio JO, Brandt CD, et al. Human reovirus-like agent as the major pathogen
associated with "winter" gastroenteritis in hospitalized infants and young children. N Engl J Med. 1976 Apr 29. 294(18):965-72.
[Medline].
53. Klasco R. Colorado tick fever. Med Clin North Am. 2002 Mar. 86(2):435-40, ix. [Medline].
54. Kovacs A, Chan L, Hotrakitya C, Overturf G, Portnoy B. Rotavirus gastroenteritis. Clinical and laboratory features and use of the
Rotazyme test. Am J Dis Child. 1987 Feb. 141(2):161-6. [Medline].
55. Lane RS, Emmons RW, Devlin V, Dondero DV, Nelson BC. Survey for evidence of Colorado tick fever virus outside of the known
endemic area in California. Am J Trop Med Hyg. 1982 Jul. 31(4):837-43. [Medline].
56. Lerner AM, Cherry JD, Klein JO, Finland M. Infections with reoviruses. N Engl J Med. 1962 Nov 8. 267:947-52. [Medline].
57. Madore HP, Christy C, Pichichero M, Long C, Pincus P, Vosefsky D, et al. Field trial of rhesus rotavirus or human-rhesus rotavirus
reassortant vaccine of VP7 serotype 3 or 1 specificity in infants. The Elmwood, Panorama, and Westfall Pediatric Groups. J Infect
Dis. 1992 Aug. 166(2):235-43. [Medline].
58. Major AS, Rubin DH, Cuff CF. Mucosal immunity to reovirus infection. Curr Top Microbiol Immunol. 1998. 233 Reovir.ii:163-77.
[Medline].
59. Mandell GL, Bennett JE, Dolin R. Principles and Practice of Infectious Diseases. Vol 2. St. Louis, Mo:. Mosby. 2000:1693-1703.
60. Matson DO, O'Ryan ML, Herrera I, Pickering LK, Estes MK. Fecal antibody responses to symptomatic and asymptomatic rotavirus
infections. J Infect Dis. 1993 Mar. 167(3):577-83. [Medline].
61. McLean RG, Shriner RB, Pokorny KS, Bowen GS. The ecology of Colorado tick fever in Rocky Mountain National Park in 1974. III.
Habitats supporting the virus. Am J Trop Med Hyg. 1989 Jan. 40(1):86-93. [Medline].
62. Meurman OH, Laine MJ. Rotavirus epidemic in adults. N Engl J Med. 1977 Jun 2. 296(22):1298-9. [Medline].
63. Perez-Schael I, Garcia D, Gonzalez M, Gonzalez R, Daoud N, Perez M, et al. Prospective study of diarrheal diseases in Venezuelan
children to evaluate the efficacy of rhesus rotavirus vaccine. J Med Virol. 1990 Mar. 30(3):219-29. [Medline].
64. Perez-Schael I, Guntinas MJ, Perez M, Pagone V, Rojas AM, Gonzalez R, et al. Efficacy of the rhesus rotavirus-based quadrivalent
vaccine in infants and young children in Venezuela. N Engl J Med. 1997 Oct 23. 337(17):1181-7. [Medline].
65. Riepenhoff-Talty M, Bogger-Goren S, Li P, Carmody PJ, Barrett HJ, Ogra PL. Development of serum and intestinal antibody
response to rotavirus after naturally acquired rotavirus infection in man. J Med Virol. 1981. 8(3):215-22. [Medline].
66. Rubenstein AS, Miller MF. Comparison of an enzyme immunoassay with electron microscopic procedures for detecting rotavirus. J
Clin Microbiol. 1982 May. 15(5):938-44. [Medline].
67. Ruiz-Palacios GM, Pérez-Schael I, Velázquez FR, Abate H, Breuer T, Clemens SC, et al. Safety and efficacy of an attenuated
vaccine against severe rotavirus gastroenteritis. N Engl J Med. 2006 Jan 5. 354(1):11-22. [Medline].
68. Salmi TT, Arstila P, Koivikko A. Central nervous system involvement in patients with rotavirus gastroenteritis. Scand J Infect Dis.
1978. 10(1):29-31. [Medline].
69. Silver HK, Meiklejohn G, Kempe CH. Colorado Tick Fever. Am J Dis Child. 1961. 101:56-62.
70. Snyder JD, Merson MH. The magnitude of the global problem of acute diarrhoeal disease: a review of active surveillance data. Bull
World Health Organ. 1982. 60(4):605-13. [Medline].
71. Spruance SL, Bailey A. Colorado Tick Fever. A review of 115 laboratory confirmed cases. Arch Intern Med. 1973 Feb. 131(2):288-
93. [Medline].
72. Tallett S, MacKenzie C, Middleton P, Kerzner B, Hamilton R. Clinical, laboratory, and epidemiologic features of a viral gastroenteritis
in infants and children. Pediatrics. 1977 Aug. 60(2):217-22. [Medline].
73. Tyler KL. Pathogenesis of reovirus infections of the central nervous system. Curr Top Microbiol Immunol. 1998. 233 Reovir.ii:93-124.
[Medline].
74. Tyler KL, Sokol RJ, Oberhaus SM, Le M, Karrer FM, Narkewicz MR, et al. Detection of reovirus RNA in hepatobiliary tissues from
patients with extrahepatic biliary atresia and choledochal cysts. Hepatology. 1998 Jun. 27(6):1475-82. [Medline].
75. Virgin HW, Dermody TS, Tyler KL. Cellular and humoral immunity to reovirus infection. Curr Top Microbiol Immunol. 1998. 233(Pt
2):147-61. [Medline].
76. Walsh JA, Warren KS. Selective primary health care: an interim strategy for disease control in developing countries. N Engl J Med.
1979 Nov 1. 301(18):967-74. [Medline].
77. Walther FJ, Bruggeman C, Daniels-Bosman MS, Pourier S, Grauls G, Stals F, et al. Symptomatic and asymptomatic rotavirus
infections in hospitalized children. Acta Paediatr Scand. 1983 Sep. 72(5):659-63. [Medline].
78. Widdowson MA, Bresee JS, Gentsch JR, Glass RI. Rotavirus disease and its prevention. Curr Opin Gastroenterol. 2005 Jan.
21(1):26-31. [Medline].
79. Wright PF, Tajima T, Thompson J, Kokubun K, Kapikian A, Karzon DT. Candidate rotavirus vaccine (rhesus rotavirus strain) in
children: an evaluation. Pediatrics. 1987 Oct. 80(4):473-80. [Medline].

Reo Viruses

Hochgeladen von

Dokumentinformationen

Copyright

Verfügbare Formate

Dieses Dokument teilen

Dokument teilen oder einbetten

Freigabeoptionen

Stufen Sie dieses Dokument als nützlich ein?

Sind diese Inhalte unangemessen?

Copyright:

Verfügbare Formate

Reo Viruses

Hochgeladen von

Copyright:

Verfügbare Formate

2/25/2019 https://emedicine.medscape.

Structure and Composition

Characteristics of the Pathogen

Upper respiratory illness

Bronchiolitis obliterans-organizing pneumonia

Colorado tick fever

Epstein-Barr Virus (EBV) Infectious Mononucleosis (Mono)

Rocky Mountain Spotted Fever (RMSF)

Colorado tick fever

Colorado tick fever

Colorado tick fever

Colorado tick fever

Contributor Information and Disclosures

Disclosure: Nothing to disclose.

Specialty Editor Board

Disclosure: Received salary from Medscape for employment. for: Medscape.

Disclosure: Nothing to disclose.

Disclosure: Nothing to disclose.

Disclosure: Nothing to disclose.

Disclosure: Nothing to disclose.

Disclosure: Nothing to disclose.

Das könnte Ihnen auch gefallen